Clinical and epidemiological research

**EXTENDED REPORT**

Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study

Stephanie Finzel,1 Juergen Rech,1 Sarah Schmidt,1 Klaus Engelke,2 Matthias Englbrecht,1 Georg Schett1

**ABSTRACT**

**Introduction** Interleukin-6 receptor (IL-6R) blockade improves the signs and symptoms of rheumatoid arthritis (RA) and retards bone damage. Whether IL-6R blockade allows repair of existing bone erosions is so far unclear.

**Methods** This study examined bone erosions in the metacarpophalangeal joints of 20 patients receiving treatment with the IL-6R blocker tocilizumab using micro CT (μCT). The maximal width and depth of individual bone erosions was measured at baseline and after 1 year of treatment.

**Results** 133 bone erosions were identified at baseline with a mean (±SD) size of 2.23±1.26 mm and depth of 2.16±1.50 mm. Distribution analysis showed predominant involvement of the second compared with the third and fourth metacarpophalangeal joints, the metacarpal heads compared with the phalangeal bases and the radial quadrants compared with all other surfaces. Repair of bone erosions during tocilizumab treatment was confined to those lesions showing sclerosis at baseline and/or at follow-up and those with a width larger than 1.6 mm. The mean decrease in width of sclerosed erosions was thus 0.14±0.05 mm (p=0.0086) and 0.20±0.08 mm (p=0.019) for sclerosing lesions after 1 year of treatment.

**Conclusions** Blockade of IL-6R by tocilizumab can induce limited repair in a subset of erosions, particularly in large lesions with sclerosis. Repair of erosions during tocilizumab treatment reflects the favourable impact of IL-6R blockade on local bone remodelling in patients with RA.

Bone erosion is a hallmark of rheumatoid arthritis (RA) reflecting the tight interaction between inflammation, structural damage and functional disability.1–3 Bone erosion results from a chronic inflammatory process in the synovial membrane and adjacent bone marrow, which triggers skeletal damage particularly at the ‘bare areas’ of the joint, where bone is not covered by cartilage. Pathogenesis of bone erosion is based on local expression of inflammatory cytokines, such as the receptor activator of nuclear factor kappa B ligand (RANKL) and tumour necrosis factor (TNF) alpha, which stimulate the differentiation of synovial monocytes/macrophages into osteoclasts and triggers the resorption of cortical bone.4 Destruction of bone and the covering cartilage has been shown to be closely related to functional decline in RA patients,2,5 and antirheumatic therapies attempt to retard, stop or even reverse structural bone damage in arthritis to maintain or even improve the patients’ disease state.6

Antirheumatic drugs show specific effects on the periaricular bone, which are related to the magnitude and the quality of their bone-protective action.7 Bone-protective effects of antirheumatic drugs are usually based on their anti-inflammatory properties, which allow control of synovitis, and their direct effects on the bone-resorptive process by affecting osteoclast differentiation. Retardation and even arrest of progression of bone erosion is a well-known effect of antirheumatic drugs, which appears to be particularly strong with TNF blocking agents. Much less, however, is known about the possibility of repair of existing bone erosions and whether and how cytokine blockade influences this process.

The principal possibility of repair of existing bone erosions has been obtained from radiographic studies,6–9 which have been later supported by MRI, CT and ultrasound.10 11 We have recently developed a high-resolution imaging technique to measure the dimensions of single bone erosions exactly.12 Its high resolution combined with direct visualisation of bone allows micro CT (μCT) to detect even tiny changes in the dimensions of single bone erosions and thereby allows the assessment of repair. By using μCT, it has been shown that repair is associated with the apposition of bone at the bottom of the lesions resulting in partial refilling of the lesions.13 It is unknown whether other cytokine-blocking strategies also allow repair of existing bone erosions. We therefore decided to search for evidence of repair in RA patients treated with the neutralising interleukin-6 receptor (IL-6R) antibody tocilizumab, because interleukin 6 (IL-6) has been shown to regulate bone homeostasis by affecting osteoblast and osteoclast function.14 To accomplish this goal, we performed a sequential μCT analysis of bone erosions in RA patients treated with tocilizumab over 1 year to determine exactly the occurrence of repair.

**METHODS**

**Patients** Twenty RA patients were included in this study. All patients fulfilled the 1987 American Rheumatism Association revised criteria for the classification of...
informed consent was obtained for the study. Approval from the local ethics committee and national radiation safety agency (Bundesamt für Strahlenschutz) as well as written informed consent was obtained for the study. The study was performed in accordance with the Declaration of Helsinki.

Results

Baseline characteristics of patients and bone erosions

Twenty patients receiving tocilizumab therapy were included in this study: all of them were followed over 1 year and received µCT-based assessment of the second, third and fourth metacarpophalangeal joints to measure exactly all bone erosions at baseline after 1 year for reassessment. Seventeen patients were women and three were men, with a mean±SD age of 50.7±13.5 years and a mean±SD disease duration of 11.1±8.8 years. Mean disease activity at baseline according to the disease activity score using 28 joint counts (DAS28) was 5.48±2.38, at baseline showing active disease with significant improvement in the signs and symptoms of RA after 1 year (mean±SD DAS28 3.25±1.13).

We found at total number of 133 bone erosions at baseline. All these 133 lesions could be visualised again at follow-up examination. In addition, nine new erosions were detected at follow-up. The mean (±SD) width of bone erosions was 2.23±1.26 mm, mean (±SD) depth was 2.16±1.50 mm. Erosions showed a standard distribution pattern, as reported previously, with preferential involvement of the second (49%) and fourth (22%) metacarpophalangeal joints, the metacarpals (62%) compared with the phalangeal bases (38%) and the radial joint compartment (37%) compared with the ulnar (26%), dorsal (19%) and palmar (18%) joint compartments (figure 1).

Effects of tocilizumab therapy on the size of individual bone erosions

We next compared the changes in maximal width and depth of the 133 bone erosions found at baseline and follow-up examination. The width of bone erosions significantly (p=0.014)
Evidence for repair of bone erosions in rheumatoid arthritis patients treated with tocilizumab. (A, B) Changes in maximal width (A) and depth (B) of individual bone erosions from baseline after 1 year of tocilizumab treatment. Results are shown for all erosive lesions and subsets with signs of sclerosis at baseline and follow-up (scleroses), with sclerosis only at follow-up (sclerosing) and those with no signs of sclerosis (non-sclerosing). Red bars indicate 95% CI. (C) Representative bone erosions (white arrows) at base line and follow-up. Asterisks indicate significant difference from baseline (* \( p < 0.05 \), ** \( p < 0.01 \)).

Erosion size and repair in RA patients treated with tocilizumab

We next analysed whether the size of erosions predicts repair. We therefore created quartiles according to the width and depth of bone erosions (figure 4A, B). We performed this analysis for both sclerosed and sclerosing bone erosions, as evidence of repair was confined to these two categories of erosions. Analysis of different quartiles for erosion width showed that repair was confined to larger lesions of more than 1.76 mm (quartiles 3 and 4; both \( p < 0.05 \)) for sclerosed lesions and 2.55 mm (quartiles 3 and 4; both \( p < 0.05 \)) for sclerosing lesions. Similar results were obtained when analysing the different quartiles of erosion depth. Sclerosed lesions with a depth of more than 1.60 mm (quartiles 3 and 4, both \( p < 0.05 \)) but not the smaller ones (quartiles 1 and 2) showed evidence of repair. With sclerosing lesions those over 3.31 mm in depth (quartile 4) showed a strong trend towards repair, although results did not reach statistical significance.

The preponderance of repair in larger bone erosions also became evident from the analysis of probability plots for changes in erosion width and depth. When plotting changes in erosion width and depth in patients treated with tocilizumab, lesions with repair, arrest and progression can be identified (figure 4C). Larger lesions (quartiles 3 and 4) accumulated in the left negative part of the probability plot indicating a higher prevalence of repair (figure 4D). For instance 71.4% of the lesions with evidence of substantial repair (>0.5 mm decrease in width) were larger lesions, whereas only 6.7% of lesions with substantial progression (>0.5 mm increase in width) were larger erosions.

**DISCUSSION**

By using μCT, a high-resolution imaging technique designed for the quantitative analysis of bone, we show that therapy with the IL-6R blocker tocilizumab allows limited repair of bone erosions. Although repair was incomplete and all of the 133 bone erosions detected at baseline could be revisited at follow-up, treatment with tocilizumab was associated with an improvement in the width of cortical breaks as well as their depth. Repair was closely linked to evidence of sclerosis, which probably reflects new bone formation as well as the baseline size of erosions, with larger lesions showing a higher likelihood of


**Clinical and epidemiological research**
repair. Importantly, the readers of the images were unaware of the changes in erosion width, erosion depth and sclerosis between baseline and follow-up, thus ruling out that judgement on the presence or absence of sclerosis influenced data on the changes in erosion width and depth.

Several previous studies have reported that repair of bone erosions can occur in RA patients. Several previous studies have reported that repair of bone erosions can occur in RA patients.6–11 13 These studies, however, have also suggested that repair is limited and confined to a subset of lesions.10 11 13 RA patients treated with TNF inhibitors appear preferentially to show evidence of repair.6–11 13 We recently confirmed this notion by a μCT study, which showed clear evidence for the limited repair of bone erosions in patients treated with TNF inhibitors compared with patients treated with methotrexate.13 Interestingly, erosion repair on treatment with TNF inhibitors is also almost exclusively confined to larger lesions with evidence of sclerosis, which is in high accordance with our new data obtained in RA patients treated with tocilizumab. Why larger erosions show a higher likelihood of repair than smaller lesions is not fully understood, but may involve contact with the bone marrow space required to induce the skeletal repair process and time factors, as osteoblastic responses require time to allow sufficient cell differentiation, deposition of matrix and mineralisation and larger lesions may be older.

Whether there is evidence of erosion repair in tocilizumab-treated RA patients, as previously reported in TNF inhibitor-treated RA patients, remains speculative. Despite similar baseline erosion size and a very similar mean change in the size of bone erosions after 1 year among the previously analysed TNF inhibitor-treated RA patient cohort and this cohort of tocilizumab-treated RA patients, their baseline erosion count was substantially different, with significantly more baseline bone erosions in the tocilizumab cohort. Therefore, we could not perform a direct comparison of the two patient groups as the likelihood of repair may depend on the baseline erosion count. It can be speculated, however, that the degree of erosion repair is comparable in tocilizumab and TNF inhibitor-treated RA patients as the higher baseline erosion count in the tocilizumab cohort is a negative selection bias and may underestimate the potential of tocilizumab to induce repair of existing bone lesions. Qualitative differences, however, may exist in the repair of erosions between IL-6 and TNF blockade. IL-6 blockade thus also affects the size of the cortical break (erosion width), whereas erosion repair during TNF blockade is exclusively based on the reduction of erosion depth,13 which may indicate the preferential use of either periosteal and endosteal repair processes among these two cytokine-blocking modalities.

The pathophysiological background of the limited repair of bone erosions in RA patients treated with tocilizumab is probably based on the effects of IL-6 on bone remodelling. IL-6 is a strong inducer of osteoclast differentiation by at least two different pathways. It can directly stimulate differentiation of mononuclear cells to osteoclasts by forming complexes with the soluble IL-6R followed by stimulation of osteoclasts lineage cells through the membrane-bound glycoprotein 150.18–21 Blockade of the IL-6R by neutralising antibodies has recently been shown to abrogate this direct osteoclastogenic effect of IL-6.22 In addition, IL-6 also acts on osteoblast lineage cells, where it induces RANKL and indirectly stimulates osteoclastogenesis.23–27 Both the direct and indirect inhibition of osteoclast differentiation explains the significant differences in IL-6 blockage observed in these studies. Whether the different inhibition of osteoclast differentiation explains the different repair observed in these studies is still unclear. It remains to be determined whether these differences in IL-6 blockage observed in these studies are responsible for the differences in repair observed in these studies.

Figure 4 Size of bone erosions and evidence of repair. Mean±SD changes of erosion width (A) and erosion depth (B) in lesions showing sclerosis at baseline and follow-up (sclerosed) and follow-up only (sclerosing). Data re shown for the quartiles of erosion width and depth at baseline (Q1 to Q4, with Q1 resembling the smallest lesions and Q4 the largest lesions). (C) Probability plot showing the absolute changes in erosion width (red) and depth (blue) for each single bone erosion. Negative values on the left indicate repair, whereas positive values on the right indicate progression of lesions. (D) Probability plot showing absolute changes in the width (left, red) and depth (right, blue) of all bone erosions as well as those of the quartiles Q3 and Q4 of erosion size (larger lesions, black).
by, for instance, affecting osteoblast recruitment and differentiation is not fully clear. Strong evidence for a shift towards increased bone formation, however, comes from the sequential analysis of bone biomarkers in the randomised controlled OPTION trial. In that study, biomarkers of bone formation such as osteocalcin and N-terminal propeptide of type I collagen showed a significant increase from baseline in response to tocilizumab. Preliminary data from the effects of tocilizumab in juvenile idiopathic arthritis, in which bone formation is blunted by inflammation and leads to growth retardation of the affected child, suggests that the blockade of IL-6R restores normal bone formation facilitating normal skeletal development and repair.

These favourable effects of IL-6R blockade on bone formation may be primarily based on the effective blockade of inflammation as the role of IL-6 on osteoblast lineage cells is not necessarily detrimental. Although data have suggested that IL-6 may block osteoblast function, and mice transgenic for IL-6 show low bone formation, other data revealed that IL-6 is important for osteoblast recruitment and may even foster osteoblast differentiation by the induction of insulin-like growth factor 1. In summary, these data show that IL-6R blockade is associated with repair of bone erosions in patients with RA. Repair is based on reduction in the width and depth of the erosion, which is somewhat different from the effect of TNF inhibitors, in which repair is based on lowering erosion depth but not width. Repair with tocilizumab is, however, limited, as observed with TNF inhibitors, and does not lead to complete healing of erosions, which suggests that current antirheumatic therapies have a rather limited potential to induce the repair of bone lesions.

Contributors SF, JR, SS and KE performed data acquisition and analysis. ME performed statistical analysis and GS drafted the manuscript.

Funding This study was supported by the Deutsche Forschungsgemeinschaft (FG 661/FP4 and SP11488-IMMUNOBONE), the Bundesministerium für Bildung und Forschung (BMBF; project ANCYLOSS), the MASTERSWITCH project of the European Union and the IMI-funded project BT Cure.

Competing interests None.

Ethics approval Approval from the University of Erlangen-Nuremberg ethics committee and national radiation safety agency (Bundesamt für Strahlenschutz) was obtained for the study.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study
Stephanie Finzel, Juergen Rech, Sarah Schmidt, Klaus Engelke, Matthias Englbrecht and Georg Schett

Ann Rheum Dis 2013 72: 396-400 originally published online May 14, 2012
doi: 10.1136/annrheumdis-2011-201075